MDXH - Utang jangka dawa perusahaan MDxHealth Inc.

MDxHealth SA (MDXH) is developing its prostate cancer molecular screening segment, the results of which assist physicians and insurers in determining therapy strategies. These technologies have become the primary profit generator, producing a consistent operational cash flow. The inclusion of these tests in medical protocols ensures steady demand, with the indicator standing at 0.00. The long-term liability cost chart below demonstrates the financial stability of this business.

MDxHealth SA specializes in proprietary molecular diagnostics for urological oncological diseases, possessing an exclusive market advantage. An analysis of the organization's long-term financial debt allows for an assessment of the total volume of credit obligations with a maturity of more than one year. Growth in this metric increases financial leverage, yet creates risks of capital depreciation as the cost of borrowed financing rises. The stability of this indicator confirms the resilience of the business model given its high level of technological protection.